TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04399148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study: NCT04046406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR neurography-guided cryoanalgesia
Description: Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
Study: NCT02486887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemonitoring of weight, pulse and blood pressure
Study: NCT02389712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
Study: NCT03611517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual rehabilitation programme
Description: The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
Study: NCT03835000

Intervention type: PROCEDURE
Intervention: Orthopedic surgery
Description: before and after surgery, patient will need medical imaging to asses their conditions
Study: NCT04399148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 MG
Description: Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 MG
Description: Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 MG
Description: Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study: NCT02250235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health risk information
Study: NCT00873769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 10 mg
Description: Staccato Loxapine 10 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 10 mg
Description: Staccato Loxapine 10 mg, single dose
Study: NCT03830814

Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
Study: NCT03906435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
Study: NCT01904071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UFNB (Ultrasound guided femoral nerve block)
Description: Ultrasound Guided Femoral Nerve Block
Study: NCT02242227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent® Diskus®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (HandiHaler®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (HandiHaler®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Diskus®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Diskus®)
Study: NCT03657667

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ureteroscopy
Description: Endoscopic removal of kidney stones
Study: NCT04436809

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel Node Biopsy
Description: Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel Node Biopsy
Description: Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary Dissection
Description: Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
Study: NCT00478725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, oral
Description: oral, 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, oral
Description: oral, 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, IV
Description: IV, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, radiolabeled oral
Description: oral, 400 mg radiolabeled
Study: NCT01278017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: ceftriaxone ,parenteral route, 50mg/kg/day divided twice
Study: NCT00972829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10 or 20 milligrams once or twice a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 5 or 10 milligrams
Study: NCT03666975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIV 30 Hz
Description: LivMD LIV platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIV 30 Hz
Description: LivMD LIV platform
Study: NCT01361919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feedback During CPR Training and Testing
Description: Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Feedback During CPR Training and Testing
Description: Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No Feedback Group
Description: A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feedback during CPR Training Not Testing
Description: Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
Study: NCT03411265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered, e-health application
Description: RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention.
Study: NCT04504370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Study: NCT03000374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study: NCT01904071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVMS (IV Morphine)
Description: Intravenous Morphine
Study: NCT01533870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: Oral 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NKTR-118
Description: Oral 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Oral 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Oral 600 mg
Study: NCT02694835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses with UV Absorber

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lenses
Study: NCT03001843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Anesthesia of only Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcotics
Description: The narcotic group will receive no ketamine but rather a more standard anesthetic
Study: NCT02064959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temperature management Zoll Intravascular Temperature Management device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature management Zoll Intravascular Temperature Management device
Study: NCT04425629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab combination therapy
Description: Administered intravenously (IV) single dose
Study: NCT01681381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tivoli® DES
Description: Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tivoli® DES
Description: Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Firebird2® DES
Description: The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firebird2® DES
Description: The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
Study: NCT02925351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Clofarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT06217874

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT00816751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block
Description: The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracervical
Description: The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buffered Lidocaine, vasopressin, sodium bicarbonate
Description: The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine, vasopressin, sodium bicarbonate
Description: The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
Study: NCT04738058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin Supplement
Description: Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02708069

Intervention type: OTHER
Group type: OTHER
Intervention: e-Unstuck
Description: An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.

Intervention type: OTHER
Group type: OTHER
Intervention: Unstuck and On Target
Description: An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
Study: NCT04693130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based prenatal education
Description: Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hospital-based antenatal care
Description: Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
Study: NCT01292252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Teriparatide 20 ug subcutaneous injection daily for 12 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT02267967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
Study: NCT01580319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: 150 minutes per week
Study: NCT01171625

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of CEP Magna Ease Model 3300TFX
Description: Heart Valve Surgery
Study: NCT04404881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Induction Period (first 3 months of bevacizumab treatment):~  -- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks.
Study: NCT02071836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right Turns web application
Study: NCT03738176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone in orabase
Description: triamcinolone 140 gm-Na CMC 50 gm